Biofrontera Inc. (BFRI) |
|
0.6 -0.02 (-3.23%)
|
03-27 16:00 |
|
Open: |
0.6477 |
Pre. Close: |
0.62 |
|
High:
|
0.6477 |
Low:
|
0.5801 |
|
Volume:
|
40,954 |
Market Cap:
|
16(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:17:41 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.83  One year: 0.95 |
| Support: |
Support1: 0.55 Support2: 0.45 |
| Resistance: |
Resistance1: 0.71 Resistance2: 0.81 |
| Pivot: |
0.61 |
| Moving Average: |
MA(5): 0.6 MA(20): 0.62
MA(100): 0.86 MA(250): 1.57 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 40.7 %D(3): 36 |
| RSI: |
RSI(14): 36.7 |
| 52-week: |
High: 6.11 Low: 0.55 |
| Average Vol(K): |
3-Month: 117 (K) 10-Days: 56 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BFRI ] has closed above bottom band by 41.0%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.62 - 0.63 |
0.63 - 0.63 |
|
Low:
|
0.58 - 0.59 |
0.59 - 0.59 |
|
Close:
|
0.61 - 0.62 |
0.62 - 0.63 |
|
Company Description |
|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. |
Headline News |
Mon, 27 Mar 2023
Biofrontera Inc. (BFRI) Makes Transformative Investment in Its ... - StreetInsider.com
Fri, 17 Mar 2023
Why Sarepta Therapeutics Shares Are Trading Lower By Around 19 ... - Investing.com UK
Fri, 17 Mar 2023
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting - Yahoo Finance
Thu, 09 Mar 2023
Benchmark Reaffirms Buy Rating and $7 Price Target for Biofrontera - Best Stocks
Thu, 09 Mar 2023
Biofrontera Inc. (NASDAQ:BFRI) Q4 2022 Earnings Call Transcript - Yahoo Finance
Thu, 02 Mar 2023
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
27 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
42.3 (%) |
|
% Held by Institutions
|
7.4 (%) |
|
Shares Short
|
236 (K) |
|
Shares Short P.Month
|
386 (K) |
Stock Financials |
|
EPS
|
-0.03 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.88 |
|
Profit Margin (%)
|
-2.3 |
|
Operating Margin (%)
|
-75.1 |
|
Return on Assets (ttm)
|
-25.9 |
|
Return on Equity (ttm)
|
-3.7 |
|
Qtrly Rev. Growth
|
10.6 |
|
Gross Profit (p.s.)
|
0.5 |
|
Sales Per Share
|
1.07 |
|
EBITDA (p.s.)
|
-0.79 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
2 (M) |
Stock Valuations |
|
PE Ratio
|
-20.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.67 |
|
Price to Sales
|
0.55 |
|
Price to Cash Flow
|
-0.99 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
